Objectives To define the incidence of high residual gradient (HRG) after transcatheter aortic valve replacement (TAVR) in BAVs and their impact on short term outcome and 1-year mortality. Background Transcatheter heart valves (THVs) offer good performance in tricuspid aortic valves with low rate of HRG. However, data regarding their performance in bicuspid aortic valves (BAV) are still lacking. Methods The BEAT (Balloon vs Self-Expandable valve for the treatment of bicuspid Aortic valve sTenosis) registry included 353 consecutive patients who underwent TAVR (Evolut R/PRO or Sapien 3 valves) in BAV between June 2013 and October 2018. The primary endpoint was device unsuccess with post-procedural HRG (mean gradient ≥ 20 mmHg). The secondary endpoint was to identify the predictors of HRG following the procedure. Results Twenty patients (5.6%) showed HRG after TAVR. Patients with HRG presented higher body mass index (BMI) (30.7 ± 9.3 vs. 25.9 ± 4.8; p  < 0.0001) and higher baseline aortic mean gradients (57.6 ± 13.4 mmHg vs. 47.7 ± 16.6, p  = 0.013) and more often presented with BAV of Sievers type 0 than patients without HRG. At multivariate analysis, BMI odds ratio (OR) 1.12; 95% confidence interval (CI) 1.05–1.20, p  = 0.001 and BAV type 0 (OR 11.31, 95% CI 3.45–37.06, p  < 0.0001) were confirmed as independent predictors of high gradient. Conclusion HRG following TAVR in BAVs is not negligible and is higher among patients with high BMI and with BAV 0 anatomy. Graphic abstract